• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma.在小细胞肺癌患者中单次静脉输注消旋体1小时后异环磷酰胺及其对映体的药代动力学。
Br J Clin Pharmacol. 1995 Apr;39(4):452-5. doi: 10.1111/j.1365-2125.1995.tb04477.x.
2
Ifosfamide enantiomers: pharmacokinetics in children.异环磷酰胺对映体：儿童药代动力学
Cancer Chemother Pharmacol. 1994;34(5):447-9. doi: 10.1007/BF00685573.
3
Enantiomeric separation of R- and S-ifosfamide and their determination in serum from clinical subjects.R-和S-异环磷酰胺的对映体拆分及其在临床受试者血清中的测定。
J Chromatogr B Biomed Appl. 1994 Mar 18;654(1):152-8. doi: 10.1016/0378-4347(93)e0446-w.
4
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.由于药物分布改变，肥胖患者异环磷酰胺消除半衰期延长。
Cancer Chemother Pharmacol. 1989;25(2):139-42. doi: 10.1007/BF00692355.
5
Enantiomer-enantiomer interaction of ifosfamide in the rat.异环磷酰胺在大鼠体内的对映体-对映体相互作用。
Xenobiotica. 2006 Jun;36(6):535-49. doi: 10.1080/00498250600659122.
6
Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients.
Cancer Chemother Pharmacol. 1996;37(5):451-6. doi: 10.1007/s002800050411.
7
Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy.分次静脉注射异环磷酰胺治疗患者中异环磷酰胺、4-羟基异环磷酰胺、氯乙醛以及2-和3-去氯乙基异环磷酰胺的比较药代动力学
Cancer Chemother Pharmacol. 1993;33(1):36-42. doi: 10.1007/BF00686020.
8
A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cycles.连续治疗周期中5日分次给药异环磷酰胺的药代动力学研究。
Br J Clin Pharmacol. 1996 Aug;42(2):179-86. doi: 10.1046/j.1365-2125.1996.03956.x.
9
Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma.
Eur J Clin Pharmacol. 2001 Sep;57(6-7):467-77. doi: 10.1007/s002280100322.
10
Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients.
Cancer Chemother Pharmacol. 2001 Jul;48(1):53-61. doi: 10.1007/s002800100277.

引用本文的文献

1
Stereoselective pharmacokinetics of ifosfamide in male and female rats.异环磷酰胺在雄性和雌性大鼠体内的立体选择性药代动力学
AAPS PharmSci. 2000;2(2):E17. doi: 10.1208/ps020217.
2
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.异环磷酰胺及其代谢产物的临床药代动力学和药效学
Clin Pharmacokinet. 2001 Jan;40(1):41-62. doi: 10.2165/00003088-200140010-00004.
3
Metabolism and pharmacokinetics of oxazaphosphorines.恶唑磷类化合物的代谢与药代动力学
Clin Pharmacokinet. 2000 Apr;38(4):291-304. doi: 10.2165/00003088-200038040-00001.
4
Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients.
Cancer Chemother Pharmacol. 1996;37(5):451-6. doi: 10.1007/s002800050411.

本文引用的文献

1
Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.
Cancer Res. 1993 Aug 15;53(16):3758-64.
2
Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide.参与异环磷酰胺活化和N-去氯乙基化的主要人肝细胞色素P450的鉴定。
Biochem Pharmacol. 1994 Mar 29;47(7):1157-63. doi: 10.1016/0006-2952(94)90387-5.
3
Ifosfamide enantiomers: pharmacokinetics in children.异环磷酰胺对映体：儿童药代动力学
Cancer Chemother Pharmacol. 1994;34(5):447-9. doi: 10.1007/BF00685573.
4
Enantiomeric separation of R- and S-ifosfamide and their determination in serum from clinical subjects.R-和S-异环磷酰胺的对映体拆分及其在临床受试者血清中的测定。
J Chromatogr B Biomed Appl. 1994 Mar 18;654(1):152-8. doi: 10.1016/0378-4347(93)e0446-w.
5
Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. I. Antitumour effect of cyclophosphamide and ifosfamide enantiomers.环磷酰胺和异环磷酰胺的 /+/R 及 /-/S 对映体生物活性的比较研究。I. 环磷酰胺和异环磷酰胺对映体的抗肿瘤作用。
Arch Immunol Ther Exp (Warsz). 1986;34(3):275-84.
6
Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma.
Cancer Res. 1989 Feb 1;49(3):753-7.
7
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.由于药物分布改变，肥胖患者异环磷酰胺消除半衰期延长。
Cancer Chemother Pharmacol. 1989;25(2):139-42. doi: 10.1007/BF00692355.
8
Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism.分次给予异环磷酰胺治疗会使异环磷酰胺代谢随时间增加。
Br J Clin Pharmacol. 1990 Nov;30(5):725-32. doi: 10.1111/j.1365-2125.1990.tb03842.x.
9
The effect of age on the pharmacokinetics of ifosfamide.年龄对异环磷酰胺药代动力学的影响。
Br J Clin Pharmacol. 1990 Jul;30(1):140-3. doi: 10.1111/j.1365-2125.1990.tb03754.x.
10
The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients.癌症患者中短时间和长时间静脉输注异环磷酰胺的药代动力学。
Br J Clin Pharmacol. 1991 Jan;31(1):77-82. doi: 10.1111/j.1365-2125.1991.tb03860.x.

在小细胞肺癌患者中单次静脉输注消旋体1小时后异环磷酰胺及其对映体的药代动力学。

Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma.

作者信息

Corlett S A, Parker D, Chrystyn H

机构信息

Postgraduate Studies in Pharmaceutical Technology, School of Pharmacy, University of Bradford.

出版信息

Br J Clin Pharmacol. 1995 Apr;39(4):452-5. doi: 10.1111/j.1365-2125.1995.tb04477.x.

DOI:10.1111/j.1365-2125.1995.tb04477.x
PMID:7640155
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1365136/
Abstract

Ifosfamide is a chiral pro-drug which is administered clinically in its racemic form. Serum concentrations of rac-ifosfamide and its enantiomers were measured in 12 patients with lung carcinoma following a mean (+/- s.d.) intravenous dose of 4.2 (0.83) g infused over 1 h. The mean (+/- s.d.) volumes of distribution (VSS) of rac, (R)- and (S)-ifosfamide were 0.61 (0.17), 0.60 (0.16) and 0.61 (0.19) l kg-1, respectively. The mean (+/- s.d.) half-lives and clearances were 6.57 (1.69), 7.12 (1.92) and 5.98 (1.52) h and 0.065 (0.013), 0.060 (0.013) and 0.072 (0.014) l h-1 kg-1 for rac, (R)- and (S)-ifosfamide, respectively. The half-life of (S)-ifosfamide was significantly (P < 0.001) shorter than that of (R)-ifosfamide and it had a significantly higher clearance (P < 0.001). There was no significant difference in the volumes of distribution of the enantiomers. The clinical significance of the faster elimination of (S)-ifosfamide is not known.

摘要

异环磷酰胺是一种手性前体药物，临床上以外消旋形式给药。对12例肺癌患者静脉输注平均（±标准差）剂量为4.2（0.83）g，历时1小时后，测定了消旋异环磷酰胺及其对映体的血清浓度。消旋、（R）-和（S）-异环磷酰胺的平均（±标准差）分布容积（VSS）分别为0.61（0.17）、0.60（0.16）和0.61（0.19）L·kg⁻¹。消旋、（R）-和（S）-异环磷酰胺的平均（±标准差）半衰期和清除率分别为6.57（1.69）、7.12（1.92）和5.98（1.52）小时以及0.065（0.013）、0.060（0.013）和0.072（0.014）L·h⁻¹·kg⁻¹。（S）-异环磷酰胺的半衰期显著（P<0.001）短于（R）-异环磷酰胺，且清除率显著更高（P<0.001）。对映体的分布容积无显著差异。（S）-异环磷酰胺更快消除的临床意义尚不清楚。